The effects of a long acting insulin on the recovery of patients with diabetic ketoacidosis

The effect of Insulin Glargine on recovery of patients with Diabetic Ketoacidosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013050713258N1

Enrollment

Registered

2013-05-29

Start date

2013-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Ketoacidosis. Diabetes mellitus with ketoacidosis

Interventions

Intervention 1: For intervention group standard treatment for ketoacidosis including intravenous infusion of Insulin Regular 0.5 units/kg plus Insulin Glargine made by the Sanofi corporation 0.4 unit

Treatment - Drugs

For intervention group standard treatment for ketoacidosis including intravenous infusion of Insulin Regular 0.5 units/kg plus Insulin Glargine made by the Sanofi corporation 0.4 units/ kg every 24 h

For control group standard treatment for ketoacidosis including intravenous Insulin Regular 0.1 units/kg until the end of ketoacidotic state will be administered

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (to be older than 12 years old; approved diabetic ketoacidosis) Exclusion criteria: (Acute cardiac infarction; advanced kidney or liver failure; patients in need for an emergent surgery; pregnancy)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood pH. Timepoint: Before the initiation of the study and in 4 hour periods until the end of the ketoacidotic state. Method of measurement: By ABG instrument.;Blood bicarbonate concentration. Timepoint: Before the initiation of the study and in 4 hour periods until the end of the ketoacidotic state. Method of measurement: In milliequivalents per liter and by ABG instrument.;Urine ketone. Timepoint: Before the initiation of the study and in 4 hour periods until the end of the ketoacidotic state. Method of measurement: By urine test tape.;Admition time. Timepoint: From admition until discharge. Method of measurement: Days.;Blood Glucose concentration. Timepoint: Before the initiation of the study and in 1-hour periods until the end of the ketoacidotic state. Method of measurement: In milligrams per deciliter and by Glucometer.	—

Measure

Time frame

Blood pH. Timepoint: Before the initiation of the study and in 4 hour periods until the end of the ketoacidotic state. Method of measurement: By ABG instrument.;Blood bicarbonate concentration. Timepoint: Before the initiation of the study and in 4 hour periods until the end of the ketoacidotic state. Method of measurement: In milliequivalents per liter and by ABG instrument.;Urine ketone. Timepoint: Before the initiation of the study and in 4 hour periods until the end of the ketoacidotic state. Method of measurement: By urine test tape.;Admition time. Timepoint: From admition until discharge. Method of measurement: Days.;Blood Glucose concentration. Timepoint: Before the initiation of the study and in 1-hour periods until the end of the ketoacidotic state. Method of measurement: In milligrams per deciliter and by Glucometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJalil Houshyar

Tabriz University of Medical Sciences

jalilhoushyar@yahoo.com+98 41 1335 7310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026